BioSpace News Archive

Syndax Pharmaceuticals announced its treatment for mixed-lineage leukemia demonstrated robust clinical activity in a Phase I/II study.

Science-driven VC firm The Column Group set up its debut crossover fund with an oversubscribed $824 million to start.

New collaborative offers mass vaccination sites an essential network to support 200 million vaccinations in 100 days

Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its full financial results for the first quarter of 2021 after the close of market on Monday, May 10. Company management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

Regulatory News: EOS imaging (Euronext, FR0011191766 - EOSI - Eligible PEA - PME) (Paris:EOSI), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, today announces its consolidated annual results for the year to December 31, 2020 as approved by the Board of Directors on April 20, 2021. Unaudited revenues for the first quarter of 2021 also released.

NuSpine Franchise Systems, the fastest growing chiropractic franchise in the US with 166 Area Representatives licenses sold in 10 states in a little over a year, NuSpine continues its expansion across the country from California to North Carolina

Michael Fisher, president and CEO of Cincinnati Children’s Hospital Medical Center, announced he intends to retire after leading the health care system for nearly 12 years.

Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 4, 2021.

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers, today announced the closing of its initial public offering of 9,000,000 shares of its common stock at a public offering price of $17.00 per share.

Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced financial results for the quarter ended March 31, 2021.